Valeant CEO says was in talks with Sprout for three weeks

Your Health Matters

NEW YORK (Reuters) – Valeant Pharmaceuticals International Chief Executive J. Michael Pearson said Thursday on CNBC the company had been in talks to buy female libido drug company Sprout Pharmaceuticals for about three weeks prior to signing the $1 billion deal.
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave